151. Identification of ALK Gene Alterations in Urothelial Carcinoma
- Author
-
Scott J. Rodig, David M. Berman, Heinz Himmelbauer, Irmgard Costa, Joaquim Bellmunt, Marta Salido, Clara Montagut, Robert O'Brien, Sabina Signoretti, Shamini Selvarajah, Stephanie A. Mullane, Lillian Werner, Jonathan E. Rosenberg, Andre P. Fay, Silvia de Muga, Toni K. Choueiri, Jordi Barretina, Beatriz Bellosillo, Philip W. Kantoff, and André E. Minoche
- Subjects
Male ,Urologic Neoplasms ,DNA Copy Number Variations ,Colorectal cancer ,lcsh:Medicine ,In situ hybridization ,Biology ,medicine.disease_cause ,hemic and lymphatic diseases ,Basic Cancer Research ,Medicine and Health Sciences ,medicine ,Carcinoma ,Humans ,Anaplastic lymphoma kinase ,Anaplastic Lymphoma Kinase ,lcsh:Science ,In Situ Hybridization, Fluorescence ,Aged ,Neoplasm Staging ,Tumors ,Chromosome Aberrations ,Comparative Genomic Hybridization ,Mutation ,Multidisciplinary ,Bladder cancer ,lcsh:R ,Genetic Variation ,High-Throughput Nucleotide Sequencing ,Receptor Protein-Tyrosine Kinases ,Cancers and Neoplasms ,Middle Aged ,Prognosis ,medicine.disease ,Immunohistochemistry ,Bladder Cancer ,Genitourinary Tract Tumors ,Oncology ,Còlon -- Càncer ,Cancer research ,lcsh:Q ,Female ,Càncer -- Tractament ,Gene Deletion ,Research Article ,Comparative genomic hybridization - Abstract
Includes supplementary materials for the online appendix. Includes supplementary materials for the online appendix. Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene alterations in urothelial carcinoma (UC) and its correlation with clinical or pathologic features and outcome. Samples from patients with advanced UC and correlative clinical data were collected. Genomic imbalances were investigated by array comparative genomic hybridization (aCGH). ALK gene status was evaluated by fluorescence in situ hybridization (FISH). ALK expression was assessed by immunohistochemistry (IHC) and high-throughput mutation analysis with Oncomap 3 platform. Next generation sequencing was performed using Illumina Genome Analyzer IIx, and Illumina HiSeq 2000 in the FISH positive case. 70 of 96 patients had tissue available for all the tests performed. Arm level copy number gains at chromosome 2 were identified in 17 (24%) patients. Minor copy number alterations (CNAs) in the proximity of ALK locus were found in 3 patients by aCGH. By FISH analysis, one of these samples had a deletion of the 5′ALK. Whole genome next generation sequencing was inconclusive to confirm the deletion at the level of the ALK gene at the coverage level used. We did not observe an association between ALK CNA and overall survival, ECOG PS, or development of visceral disease. ALK genomic alterations are rare and probably without prognostic implications in UC. The potential for testing ALK inhibitors in UC merits further investigation but might be restricted to the identification of an enriched population.
- Published
- 2014
- Full Text
- View/download PDF